E-viri
Recenzirano
Odprti dostop
-
Vergori, Alessandra; Cozzi Lepri, Alessandro; Cicalini, Stefania; Matusali, Giulia; Bordoni, Veronica; Lanini, Simone; Meschi, Silvia; Iannazzo, Roberta; Mazzotta, Valentina; Colavita, Francesca; Mastrorosa, Ilaria; Cimini, Eleonora; Mariotti, Davide; De Pascale, Lydia; Marani, Alessandra; Gallì, Paola; Garbuglia, AnnaRosa; Castilletti, Concetta; Puro, Vincenzo; Agrati, Chiara; Girardi, Enrico; Vaia, Francesco; Antinori, Andrea; Amendola, Alessandra; Baldini, Francesco; Bellagamba, Rita; Bettini, Aurora; Bordi, Licia; Camici, Marta; Casetti, Rita; Costantini, Sarah; Cristofanelli, Flavia; D’Alessio, Claudia; D’Aquila, Veronica; De Angelis, Alessia; De Zottis, Federico; de Pascale, Lydia; Francalancia, Massimo; Fusto, Marisa; Gagliardini, Roberta; Gramigna, Giulia; Grassi, Germana; Grilli, Elisabetta; Grisetti, Susanna; Iafrate, Denise; Lapa, Daniele; Lorenzini, Patrizia; Masone, Erminia; Marongiu, Stefano; Mondi, Annalisa; Notari, Stefania; Ottou, Sandrine; Paulicelli, Jessica; Pellegrino, Luca; Pinnetti, Carmela; Plazzi, Maria Maddalena; Possi, Adriano; Sacchi, Alessandra; Tartaglia, Eleonora
Nature communications, 08/2022, Letnik: 13, Številka: 1Journal Article
Abstract In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm 3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm 3 (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log 2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
